Syn 2869

structure in first source

Also Known As:

2-(2,4-difluorophenyl)-3-(4-(4-(2-(4-trifluoromethoxybenzyl)-2H-1,2,4-triazol-3-one-4-yl)phenyl)piperazin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; Syn-2869

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - Syn 2869: 3
  - Piperazines: 26
    - Syn 2869: 3

Experts

1.	Bu, H Z: 1 article (04/2000)
2.	Daneshtalab, M: 1 article (04/2000)
3.	Khan, J K: 1 article (04/2000)
4.	Micetich, R G: 1 article (04/2000)
5.	Montaseri, H: 1 article (04/2000)
6.	Poglod, M: 1 article (04/2000)
7.	Salama, S M: 1 article (04/2000)
8.	Zuo, Z: 1 article (04/2000)

Related Diseases

1.	Infections 05/01/1999 - "Our results suggest that Syn-2869 could be effective against a range of mold infections in humans."
2.	Respiratory Tract Infections (Respiratory Tract Infection) 04/01/2000 - "The higher level of distribution of SYN-2869 into lung tissue was considered to contribute to the potent efficacy in respiratory tract infection models compared with the potency of itraconazole. "
3.	Mycoses (Diseases, Fungus) 11/01/1998 - "At the ICAAC several sessions were held which focused on the pathogenesis of fungal disease, the in vitro susceptibility testing of new azole (voriconazole, Syn-2869, SCH-56592, carbendazim), echinocandin-like (FK-463, LY-303366, MK-0991), polyene (patricins) and established antifungal agents (fluconazole, itraconazole, amphotericin B, nystatin, terbinafine), the experimental in vivo activity of these new antifungal drugs in various animal models of fungal disease, and the clinical activity of fluconazole, itraconazole and liposomal amphotericin B formulations."
4.	Body Weight (Weight, Body) 04/01/2000 - "SYN-2836, SYN-2869, SYN-2903, and SYN-2921 were rapidly absorbed into the systemic circulation and reached maximum concentrations (C(max)s) of 7.31 +/- 2.53, 6.29 +/- 0.85, 6.16 +/- 0.39, and 3.41 +/- 0.34 microg/ml, respectively, in BALB/c mice after administration of an oral dose of 50 mg/kg of body weight, with bioavailability being greater than 45% in all mice. "

Related Drugs and Biologics

1.	Itraconazole (Sporanox)
2.	Voriconazole (Vfend)
3.	Echinocandins
4.	Fluconazole (Zonal)
5.	Nystatin (Mycostatin)
6.	Azoles
7.	Antifungal Agents
8.	Amphotericin B (Amphotericin)
9.	Terbinafine (Lamisil)
10.	SYN 2836